Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts have assigned Lexicon Pharmaceuticals, Inc. a consensus recommendation of "Moderate Buy", with three analysts giving hold ratings and three issuing buy ratings.
• Lexicon Pharmaceuticals reported a quarterly EPS of $0.01, surpassing expectations, and had revenue of $28.87 million, significantly higher than the forecast of $4.87 million.
• Institutional investors hold 74.70% of Lexicon's stock, with Northern Trust Corp recently increasing its position by 14.4%.

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $3.2250.

A number of analysts have commented on LXRX shares. Citigroup upped their target price on shares of Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the company a "buy" rating in a research report on Thursday, August 7th. HC Wainwright reiterated a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a report on Tuesday, September 2nd.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in LXRX. Northern Trust Corp increased its position in shares of Lexicon Pharmaceuticals by 14.4% in the 4th quarter. Northern Trust Corp now owns 1,308,651 shares of the biopharmaceutical company's stock valued at $966,000 after buying an additional 164,620 shares in the last quarter. AQR Capital Management LLC acquired a new position in Lexicon Pharmaceuticals in the first quarter valued at about $541,000. Monaco Asset Management SAM bought a new stake in shares of Lexicon Pharmaceuticals in the first quarter worth about $338,000. Acadian Asset Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the first quarter worth about $263,000. Finally, Invesco Ltd. lifted its holdings in shares of Lexicon Pharmaceuticals by 47.2% during the 2nd quarter. Invesco Ltd. now owns 420,700 shares of the biopharmaceutical company's stock valued at $398,000 after purchasing an additional 134,941 shares in the last quarter. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Stock Performance

Shares of NASDAQ:LXRX opened at $1.16 on Tuesday. The company has a current ratio of 4.16, a quick ratio of 4.16 and a debt-to-equity ratio of 0.43. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.18. The stock has a market capitalization of $421.54 million, a P/E ratio of -3.52 and a beta of 1.26. The business has a 50-day moving average price of $1.14 and a two-hundred day moving average price of $0.81.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative return on equity of 83.63%. The company had revenue of $28.87 million during the quarter, compared to analysts' expectations of $4.87 million. Equities analysts predict that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.